JP2024534231A - Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物 - Google Patents

Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物 Download PDF

Info

Publication number
JP2024534231A
JP2024534231A JP2024514574A JP2024514574A JP2024534231A JP 2024534231 A JP2024534231 A JP 2024534231A JP 2024514574 A JP2024514574 A JP 2024514574A JP 2024514574 A JP2024514574 A JP 2024514574A JP 2024534231 A JP2024534231 A JP 2024534231A
Authority
JP
Japan
Prior art keywords
seq
peptide
polypeptides
polypeptide
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514574A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534231A5 (https=
Inventor
ゴンザレス、ヨルダンカ マスフォロール
ペレス、ヒルダ、エリサ ガライ
アコスタ、オズワルド レジェス
ネグリン、ヤセル ペレラ
メネンデス、エヴェリン カバレロ
レぺス、ルイス、ハビエル ゴンザレス
ペレス、ウラジミール、アルマンド ベサーダ
ロドリゲス、シルビオ、エルネスト ペレア
ニエト、ジェラルド、エンリケ ギレン
ブランコ、ソニア ゴンザレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of JP2024534231A publication Critical patent/JP2024534231A/ja
Publication of JP2024534231A5 publication Critical patent/JP2024534231A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
JP2024514574A 2021-07-09 2022-07-07 Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物 Pending JP2024534231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2021000058A CU24766B1 (es) 2021-07-09 2021-07-09 Péptidos lineales que inhiben la fosforilación mediada por ck2
CU2021-0058 2021-07-09
PCT/CU2022/050007 WO2023280330A1 (es) 2021-07-09 2022-07-07 Péptidos lineales que inhiben la fosforilación mediada por ck2 y composiciones que los comprenden

Publications (2)

Publication Number Publication Date
JP2024534231A true JP2024534231A (ja) 2024-09-18
JP2024534231A5 JP2024534231A5 (https=) 2025-05-23

Family

ID=83080989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514574A Pending JP2024534231A (ja) 2021-07-09 2022-07-07 Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物

Country Status (11)

Country Link
US (1) US20240317827A1 (https=)
EP (1) EP4368710A1 (https=)
JP (1) JP2024534231A (https=)
KR (1) KR20240032882A (https=)
CN (1) CN117795064A (https=)
AR (1) AR126388A1 (https=)
AU (1) AU2022308094A1 (https=)
CA (1) CA3225387A1 (https=)
CU (1) CU24766B1 (https=)
MX (1) MX2024000542A (https=)
WO (1) WO2023280330A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118290537B (zh) * 2024-05-09 2025-02-07 永州中古生物技术有限公司 一种在nci-h460细胞系中对ck2起到抑制作用的多肽

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23225A1 (es) 2001-12-20 2007-08-30 Ct Ingenieria Genetica Biotech PéPTIDOS PARA EL TRATAMIENTO DEL CáNCER ASOCIADO AL VIRUS PAPILOMA HUMANO (VPH) Y DE OTROS TUMORES EPITELIALES
WO2006020207A2 (en) * 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
CA2629751A1 (en) * 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SCI REP., vol. 9(1):11018, JPN6026014959, 2019, ISSN: 0005841827 *

Also Published As

Publication number Publication date
CU24766B1 (es) 2025-08-13
WO2023280330A1 (es) 2023-01-12
CU20210058A7 (es) 2023-02-13
US20240317827A1 (en) 2024-09-26
KR20240032882A (ko) 2024-03-12
AU2022308094A1 (en) 2024-02-01
MX2024000542A (es) 2024-02-02
EP4368710A1 (en) 2024-05-15
AR126388A1 (es) 2023-10-11
CN117795064A (zh) 2024-03-29
CA3225387A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
JP7274228B2 (ja) 病気の治療のためのポリペプチド
CA2667537A1 (en) Metastin derivatives and use thereof
US20090005294A1 (en) Peptides for the Treatment of Cancer Associated with the Human Papilloma Virus (HPV) and Other Epithelial Tumors
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
US10829523B2 (en) Anti-tumor peptides and use thereof
AU2005254736B2 (en) Oligomeric peptides and their use for the treatment of HIV infections
JP2024534231A (ja) Ｃｋ２媒介リン酸化を阻害する線状ペプチド及びそれを含む組成物
WO2000073326A2 (en) Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
JP6009154B2 (ja) 細胞膜透過型ホウ素ペプチド
US10046022B2 (en) Synthetic peptide that increases radiosensitivity of tumor cells and use of same
US10745448B2 (en) Antiviral peptide and use therefor
JP2004516301A (ja) 癌治療のためのｅ２ｆ−１／サイクリン相互作用の阻害剤
Osman et al. Microwave assisted peptide synthesis of some rationally designed cell penetrating peptides from c-kit receptor
KR101323669B1 (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
CN115160406A (zh) 一类新型抗肿瘤环肽活性分子的制备方法与应用
JP7341451B2 (ja) タンパク質性化合物とその利用
JP6320469B2 (ja) 細胞膜透過型ホウ素ペプチド
US20250282820A1 (en) Peptide complex having trkb binding activity
JP2003522116A (ja) 細胞内信号伝達を攪乱させる合成ペプチド
US7259142B2 (en) Redox-stable, non-phosphorylated cyclic peptide inhibitors of SH2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use
US5731289A (en) Double-chain hemoregulatory peptides
CA2509423A1 (en) Peptides and their use for the treatment of hiv infections
WO2024094685A1 (en) Ccr2 inhibitors and methods of use
AU2024314499A1 (en) Modified polypeptide and use thereof in field of analgesia
JPWO1994005788A1 (ja) 神経栄養ペプチド

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250515

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260417